Helen R. Park, Power3's CEO, said, "This potential agreement will propel the NuroPro(R) diagnostic test to the next level affording the ability to commercialize a physician sought after test for Alzheimer's and Parkinson's Diseases. It is a win/win for both companies."
A final agreement is subject to due diligence investigation and negotiation of a definitive exclusive license and/or acquisition agreement and approval by the Boards of Directors of both companies.
NuroPro(R) is a test designed to diagnose Alzheimer's, Parkinson's, and Lou Gehrig's disease (ALS) in individuals. The test is based on proteomic technology, in which a blood serum sample is drawn from a patient, and the concentration of selected biomarkers residing in a panel of 59 blood serum protein biomarkers of neurodegenerative disease is monitored and the test determines if a patient has a Neurodegenerative disease, such as Alzheimer's, Parkinson's or Lou Gehrig's Disease (ALS).
Transgenomic is a global biotechnology company that provides unique
products and services of automated high sensitivity genetic variation and
mutation analysis. Their offerings include systems, products, discovery and
laboratory testing services to the academic and medical research, clinical
laboratory and pharmaceutical markets in the fields of Pharmacogenomics and
personalized medicine. Specific offerings include WAVE(R) DHPLC Systems,
related consumables and assay kits, Cytogenetics automated sy
|SOURCE Transgenomic, Inc.|
Copyright©2008 PR Newswire.
All rights reserved